Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00666536 · ClinicalTrials.gov registry record · Phase 4
The Effects of Moderate vs. Aggressive Treatment With Valsartan + Amlodipine on Patients With Hypertension Uncontrolled by Angiotensin-Receptor Blocker (Herein, ARB) Monotherapy
A Phase 4 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 4
- Development phase
- 728
- Enrollment target
NCT00666536 is a Phase 4 study that has completed, run by Novartis. The registered enrollment target is 728 participants.
The verdict
NCT00666536, a Phase 4 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 728 participants
- Enrollment target
Study Summary
The purpose of this trial is to compare blood pressure lowering efficacy of moderate Valsartan + Amlodipine treatment regimen (160 / 5 mg) with that of aggressive regimen (320 / 10 mg) in patients uncontrolled on ARB monotherapy, other than Valsartan
Interventions
- DRUG valsartan and amlodipine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 728 participants |
| Start Date | 2008-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00666536
The ClinicalTrials.gov registry entry for NCT00666536 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 728 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which valsartan and amlodipine is the first listed.
NCT00666536 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00666536 about?
NCT00666536 is a clinical study titled "The Effects of Moderate vs. Aggressive Treatment With Valsartan + Amlodipine on Patients With Hypertension Uncontrolled by Angiotensin-Receptor Blocker (Herein, ARB) Monotherapy". The purpose of this trial is to compare blood pressure lowering efficacy of moderate Valsartan + Amlodipine treatment regimen (160 / 5 mg) with that of aggressive regimen (320 / 10 mg) in patients uncontrolled on ARB monotherapy, other than Valsartan
What is the current status of trial NCT00666536?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 728 participants. The study started on 2008-03.
What interventions are being tested in trial NCT00666536?
The interventions under investigation include: valsartan and amlodipine (DRUG).
Who is sponsoring clinical trial NCT00666536?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.